Literature DB >> 24344258

Epstein-Barr virus nuclear antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits Sin3A to repress CDKN2A.

Sizun Jiang1, Bradford Willox, Hufeng Zhou, Amy M Holthaus, Anqi Wang, Tommy T Shi, Seiji Maruo, Peter V Kharchenko, Eric C Johannsen, Elliott Kieff, Bo Zhao.   

Abstract

Epstein-Barr virus nuclear antigen 3C (EBNA3C) repression of CDKN2A p14(ARF) and p16(INK4A) is essential for immortal human B-lymphoblastoid cell line (LCL) growth. EBNA3C ChIP-sequencing identified >13,000 EBNA3C sites in LCL DNA. Most EBNA3C sites were associated with active transcription; 64% were strong H3K4me1- and H3K27ac-marked enhancers and 16% were active promoters marked by H3K4me3 and H3K9ac. Using ENCODE LCL transcription factor ChIP-sequencing data, EBNA3C sites coincided (±250 bp) with RUNX3 (64%), BATF (55%), ATF2 (51%), IRF4 (41%), MEF2A (35%), PAX5 (34%), SPI1 (29%), BCL11a (28%), SP1 (26%), TCF12 (23%), NF-κB (23%), POU2F2 (23%), and RBPJ (16%). EBNA3C sites separated into five distinct clusters: (i) Sin3A, (ii) EBNA2/RBPJ, (iii) SPI1, and (iv) strong or (v) weak BATF/IRF4. EBNA3C signals were positively affected by RUNX3, BATF/IRF4 (AICE) and SPI1/IRF4 (EICE) cooccupancy. Gene set enrichment analyses correlated EBNA3C/Sin3A promoter sites with transcription down-regulation (P < 1.6 × 10(-4)). EBNA3C signals were strongest at BATF/IRF4 and SPI1/IRF4 composite sites. EBNA3C bound strongly to the p14(ARF) promoter through SPI1/IRF4/BATF/RUNX3, establishing RBPJ-, Sin3A-, and REST-mediated repression. EBNA3C immune precipitated with Sin3A and conditional EBNA3C inactivation significantly decreased Sin3A binding at the p14(ARF) promoter (P < 0.05). These data support a model in which EBNA3C binds strongly to BATF/IRF4/SPI1/RUNX3 sites to enhance transcription and recruits RBPJ/Sin3A- and REST/NRSF-repressive complexes to repress p14(ARF) and p16(INK4A) expression.

Entities:  

Keywords:  EBV; lymphoma; resting B lymphocyte; tumor suppressor

Mesh:

Substances:

Year:  2013        PMID: 24344258      PMCID: PMC3890834          DOI: 10.1073/pnas.1321704111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  A role for SKIP in EBNA2 activation of CBF1-repressed promoters.

Authors:  S Zhou; M Fujimuro; J J Hsieh; L Chen; S D Hayward
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  Epstein-Barr virus nuclear protein EBNA3C residues critical for maintaining lymphoblastoid cell growth.

Authors:  Seiji Maruo; Yi Wu; Taku Ito; Teru Kanda; Elliott D Kieff; Kenzo Takada
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

3.  Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase.

Authors:  L Nagy; H Y Kao; D Chakravarti; R J Lin; C A Hassig; D E Ayer; S L Schreiber; R M Evans
Journal:  Cell       Date:  1997-05-02       Impact factor: 41.582

4.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

5.  Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase.

Authors:  Jason S Knight; Nikhil Sharma; Erle S Robertson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-13       Impact factor: 11.205

6.  Epstein-Barr virus nuclear antigen EBNA3C/6 expression maintains the level of latent membrane protein 1 in G1-arrested cells.

Authors:  M J Allday; P J Farrell
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

7.  Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro.

Authors:  B Tomkinson; E Kieff
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

8.  Epstein-Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors mSin3A and NCoR in human B-cell lines.

Authors:  Jason S Knight; Ke Lan; Chitra Subramanian; Erle S Robertson
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

9.  The EBV Latent Antigen 3C Inhibits Apoptosis through Targeted Regulation of Interferon Regulatory Factors 4 and 8.

Authors:  Shuvomoy Banerjee; Jie Lu; Qiliang Cai; Abhik Saha; Hem Chandra Jha; Richard Kuo Dzeng; Erle S Robertson
Journal:  PLoS Pathog       Date:  2013-05-02       Impact factor: 6.823

10.  Design and analysis of ChIP-seq experiments for DNA-binding proteins.

Authors:  Peter V Kharchenko; Michael Y Tolstorukov; Peter J Park
Journal:  Nat Biotechnol       Date:  2008-11-16       Impact factor: 54.908

View more
  52 in total

Review 1.  The RUNX complex: reaching beyond haematopoiesis into immunity.

Authors:  Dominic Chih-Cheng Voon; Yit Teng Hor; Yoshiaki Ito
Journal:  Immunology       Date:  2015-10-25       Impact factor: 7.397

2.  Epstein-Barr virus super-enhancer eRNAs are essential for MYC oncogene expression and lymphoblast proliferation.

Authors:  Jun Liang; Hufeng Zhou; Catherine Gerdt; Min Tan; Tyler Colson; Kenneth M Kaye; Elliott Kieff; Bo Zhao
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-18       Impact factor: 11.205

3.  Epstein-Barr virus oncoprotein super-enhancers control B cell growth.

Authors:  Hufeng Zhou; Stefanie C S Schmidt; Sizun Jiang; Bradford Willox; Katharina Bernhardt; Jun Liang; Eric C Johannsen; Peter Kharchenko; Benjamin E Gewurz; Elliott Kieff; Bo Zhao
Journal:  Cell Host Microbe       Date:  2015-01-29       Impact factor: 21.023

4.  Nonstructural Protein 4 of Porcine Reproductive and Respiratory Syndrome Virus Modulates Cell Surface Swine Leukocyte Antigen Class I Expression by Downregulating β2-Microglobulin Transcription.

Authors:  Pengfei Qi; Ke Liu; Jianchao Wei; Yuming Li; Beibei Li; Donghua Shao; Zhuanchang Wu; Yuanyuan Shi; Guangzhi Tong; Yafeng Qiu; Zhiyong Ma
Journal:  J Virol       Date:  2017-02-14       Impact factor: 5.103

5.  Protein inhibitor of activated STAT1 (PIAS1) inhibits IRF8 activation of Epstein-Barr virus lytic gene expression.

Authors:  Kun Zhang; Dong-Wen Lv; Renfeng Li
Journal:  Virology       Date:  2019-11-11       Impact factor: 3.616

6.  A parallelized, automated platform enabling individual or sequential ChIP of histone marks and transcription factors.

Authors:  Riccardo Dainese; Vincent Gardeux; Gerard Llimos; Daniel Alpern; Jia Yuan Jiang; Antonio Carlos Alves Meireles-Filho; Bart Deplancke
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-27       Impact factor: 11.205

Review 7.  Epstein-Barr Virus LMP1-Mediated Oncogenicity.

Authors:  Liang Wei Wang; Sizun Jiang; Benjamin E Gewurz
Journal:  J Virol       Date:  2017-10-13       Impact factor: 5.103

8.  Epstein-Barr Virus Nuclear Antigen 3 (EBNA3) Proteins Regulate EBNA2 Binding to Distinct RBPJ Genomic Sites.

Authors:  Anqi Wang; Rene Welch; Bo Zhao; Tram Ta; Sündüz Keleş; Eric Johannsen
Journal:  J Virol       Date:  2015-12-30       Impact factor: 5.103

Review 9.  Current Progress in EBV-Associated B-Cell Lymphomas.

Authors:  Yonggang Pei; Alexandria E Lewis; Erle S Robertson
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

Review 10.  Epstein-Barr virus latency: current and future perspectives.

Authors:  Bettina Kempkes; Erle S Robertson
Journal:  Curr Opin Virol       Date:  2015-10       Impact factor: 7.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.